MedTrace Logo

GnRHa Trigger in Asian Oocyte Donors- a Dose Finding Study

NCT02208986 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 165

Last updated 2017-02-06

No results posted yet for this study

Summary

The aim of this randomized single center study is to explore the most optimal dose of GnRHa used for triggering of final oocyte maturation in IVF. The study group will consist of oocyte donors who have GnRHa trigger as a standard trigger concept.

Hypothesis: In an Asian oocyte donor population, the use of 0.2 mg, 0.3mg or 0.4 mg of GnRHa will lead to the retrieval of comparable numbers of mature oocytes (MII) and good quality embryos. Moreover, the reproductive outcome in the recipients will be similar regardless of the dose of GnRHa used for trigger.

Conditions

  • Normal Oocyte Donors

Interventions

DRUG

Triptorelin

Triptorelin is given by s.c injection for ovulation triggering.

Sponsors & Collaborators

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • The Fertility Clinic, Skive Regional Hospital, Denmark

    collaborator UNKNOWN

  • Aarhus University Hospital

    collaborator OTHER

  • University of Southern Denmark

    collaborator OTHER

  • Vietnam National University

    lead OTHER

Principal Investigators

  • Tuong M Ho, MD · CGRH, School of Medicine, Vietnam National University HCMC, Vietnam

  • Lan TN Vuong, MD · Department of Obstetrics and Gynecology, University of Medicine and Pharmacy HCMC, Ho Chi Minh City, Vietnam

  • Peter Humaidan, MD · Aarhus University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2015-02-28
Completion
2015-03-31

Countries

  • Vietnam

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02208986 on ClinicalTrials.gov